Doshi S - Search Results

1

Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.

Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Zhu M, et al. Among authors: doshi s. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. Clin Pharmacokinet. 2016. PMID: 27209293 Clinical Trial.

2

Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.

Doshi S, Chow A, Pérez Ruixo JJ. Doshi S, et al. J Clin Pharmacol. 2010 Sep;50(9 Suppl):75S-90S. doi: 10.1177/0091270010377201. J Clin Pharmacol. 2010. PMID: 20881221

3

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT. Wang YM, et al. Among authors: doshi s. AAPS J. 2010 Dec;12(4):729-40. doi: 10.1208/s12248-010-9234-9. Epub 2010 Oct 21. AAPS J. 2010. PMID: 20963535 Free PMC article.

4

Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.

Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Sutjandra L, et al. Among authors: doshi s. Clin Pharmacokinet. 2011 Dec 1;50(12):793-807. doi: 10.2165/11594240-000000000-00000. Clin Pharmacokinet. 2011. PMID: 22087866

5

Denosumab dose selection for patients with bone metastases from solid tumors.

Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Pérez-Ruixo JJ. Doshi S, et al. Clin Cancer Res. 2012 May 1;18(9):2648-57. doi: 10.1158/1078-0432.CCR-11-2944. Epub 2012 Mar 6. Clin Cancer Res. 2012. PMID: 22394983

6

Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.

Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Gibiansky L, et al. Among authors: doshi s. Clin Pharmacokinet. 2012 Apr 1;51(4):247-60. doi: 10.2165/11598090-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22420579

7

Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Doshi S, Krzyzanski W, Yue S, Elliott S, Chow A, Pérez-Ruixo JJ. Doshi S, et al. Clin Pharmacokinet. 2013 Dec;52(12):1063-83. doi: 10.1007/s40262-013-0098-x. Clin Pharmacokinet. 2013. PMID: 23912564 Review.

8

Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.

Zhu M, Doshi S, Gisleskog PO, Oliner KS, Perez Ruixo JJ, Loh E, Zhang Y. Zhu M, et al. Among authors: doshi s. J Pharm Sci. 2014 Jan;103(1):328-36. doi: 10.1002/jps.23763. Epub 2013 Nov 1. J Pharm Sci. 2014. PMID: 24186235

9

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.

Zhu M, Tang R, Doshi S, Oliner KS, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh EY, Zhang Y. Zhu M, et al. Among authors: doshi s. Br J Cancer. 2015 Feb 3;112(3):429-37. doi: 10.1038/bjc.2014.649. Epub 2015 Jan 13. Br J Cancer. 2015. PMID: 25584489 Free PMC article. Clinical Trial.

10

Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.

Perez Ruixo JJ, Doshi S, Sohn W, Chow A. Perez Ruixo JJ, et al. Among authors: doshi s. J Clin Pharmacol. 2015 Mar;55 Suppl 3:S85-92. doi: 10.1002/jcph.388. J Clin Pharmacol. 2015. PMID: 25707967 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

494 results

Search Page

Filters